STOCK TITAN

IDEAYA Biosciences, Inc. - IDYA STOCK NEWS

Welcome to our dedicated page for IDEAYA Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on IDEAYA Biosciences stock.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is an innovative biotechnology firm concentrated on oncology. Established in 2015 and headquartered in South San Francisco and La Jolla, California, the company is dedicated to the discovery and development of precision medicine therapies for genetically defined patient groups. Their focus areas include synthetic lethality and immuno-oncology, targeting DNA damage repair mechanisms and the tumor microenvironment, respectively.

IDEAYA's pioneering approach leverages molecular diagnostics to identify and develop targeted therapeutics. The company's leading product candidate, IDE196, is a potent inhibitor of protein kinase C (PKC), aimed at treating cancers with GNAQ or GNA11 mutations. In addition, IDEAYA is advancing several clinical programs, such as the darovasertib program, which is currently in Phase 2 trials for uveal melanoma (UM) and has shown promising results in tumor shrinkage and eye preservation.

In synthetic lethality, IDEAYA's IDE397 targets methionine adenosyltransferase 2 alpha (MAT2A) in solid tumors with MTAP deletion, a condition prevalent in 15% of solid tumors. The IDE397 program includes both monotherapy and combination trials with other investigational drugs.

Financially, IDEAYA is robust with cash reserves exceeding $941.4 million as of Q1 2024, ensuring operational funding through 2028. Key investors include 5AM Ventures, Canaan Partners, and Celgene. The company has formed strategic collaborations with major pharmaceutical players like Pfizer, Amgen, Gilead Sciences, GSK, and Merck to amplify its research and clinical capabilities.

IDEAYA's scientific advisory board is composed of esteemed researchers, including a Nobel laureate and members of the National Academy of Sciences, underscoring the company's commitment to groundbreaking research.

Recent developments are promising: IDEAYA reported favorable Phase 2 trial results for IDE196 in UM, with significant tumor reduction and eye preservation rates. Additionally, a collaboration with Merck for the IDE161 program aims to tackle endometrial cancer using advanced immunotherapy combinations.

For more detailed updates and financial information, visit IDEAYA's Investor Relations page.

Rhea-AI Summary

IDEAYA Biosciences (Nasdaq: IDYA) announced the closing of its public offering, including the full exercise of underwriters' option to purchase additional shares. The offering included 8,355,714 common shares at $35.00 each and pre-funded warrants for 285,715 shares at $34.9999 each, generating approximately $302.4 million in gross proceeds. The offering was managed by J.P. Morgan, Goldman Sachs, Jefferies, and RBC Capital Markets. The final prospectus is available on the SEC's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
-
Rhea-AI Summary

IDEAYA Biosciences (Nasdaq: IDYA) has announced the pricing for its underwritten public offering of common stock and pre-funded warrants, totaling approximately $263 million in gross proceeds.

The offering includes 7,228,572 shares of common stock at $35.00 per share and 285,715 pre-funded warrants at $34.9999 per warrant. Each pre-funded warrant has an exercise price of $0.0001 per share.

Additionally, underwriters have a 30-day option to purchase up to an extra 1,127,142 shares at the public offering price. The offering is expected to close around July 11, 2024, subject to customary closing conditions.

J.P. Morgan, Goldman Sachs, Jefferies, and RBC Capital Markets are serving as joint book-running managers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
-
Rhea-AI Summary

IDEAYA Biosciences (Nasdaq: IDYA) has announced a proposed public offering of up to $200 million in common stock and pre-funded warrants.

The company will also grant underwriters a 30-day option to purchase an additional $30 million in common stock.

The offering is subject to market conditions and other factors, with no assurance of completion or specific terms.

J.P. Morgan, Goldman Sachs, Jefferies, and RBC Capital Markets are acting as joint book-running managers.

This offering will be conducted under an automatically effective shelf registration statement filed with the SEC, and will be made available via a written prospectus and a prospectus supplement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
Rhea-AI Summary

IDEAYA Biosciences announced positive interim Phase 2 monotherapy data for IDE397, a potential first-in-class MAT2A inhibitor, in MTAP-deletion urothelial and lung cancer patients. The study showed a 39% overall response rate (ORR) with 1 complete response (CR) and 6 partial responses (PRs). Disease control rate (DCR) was 94%, with 78% of patients exhibiting tumor shrinkage. Notably, 81% of patients experienced over 50% ctDNA reduction. The drug had a favorable safety profile with 5.6% grade 3 or higher adverse events and no serious adverse events. IDE397 is being evaluated for further clinical development in various cancers with MTAP deletions, addressing a significant unmet medical need.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.32%
Tags
-
Rhea-AI Summary

IDEAYA Biosciences will host an investor webcast on July 8, 2024, at 8:00 a.m. EST to report clinical data from the Phase 2 trial of IDE397 monotherapy in MTAP-deletion urothelial and non-small cell lung cancer (NSCLC). IDE397 is a MAT2A inhibitor for MTAP-deletion solid tumors. The agenda includes discussing U.S. incidence rates, patient baseline characteristics, pharmacokinetics, adverse events, clinical efficacy, and molecular response analysis. The webcast will feature CEO Yujiro S. Hata, CMO Darrin Beaupre, and CSO Michael White. Access to the webcast and updated corporate presentation will be provided on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.32%
Tags
conferences clinical trial
-
Rhea-AI Summary

IDEAYA Biosciences, a precision medicine oncology company, announced on June 28, 2024, the grant of non-qualified stock options to two newly hired employees. The options, totaling 92,000 shares, were granted under the 2023 Employment Inducement Incentive Award Plan as per Nasdaq Listing Rule 5635(c)(4).

The exercise price is set at $34.37 per share, matching the closing price of IDEAYA's stock on the grant date, June 27, 2024. The options have a 10-year term and will vest over four years, with 25% vesting on the first anniversary of the commencement date and the rest vesting monthly over the subsequent three years. Vesting is contingent on ongoing employment with IDEAYA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
none
Rhea-AI Summary

IDEAYA Biosciences has initiated a Phase 1 clinical trial for IDE397, its MAT2A inhibitor, in combination with Gilead's Trodelvy (sacituzumab govitecan-hziy) for treating MTAP-deletion bladder cancer. IDE397 targets methionine adenosyltransferase 2 alpha (MAT2A), while Trodelvy is a Trop-2 directed antibody-drug conjugate. This trial will assess safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy. MTAP-deletion is present in approximately 26% of bladder cancer patients. IDEAYA and Gilead will retain commercial rights to their respective compounds, and the trial is part of an ongoing IDEAYA-sponsored study. A data update for the IDE397 Phase 2 monotherapy expansion is expected in late 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
-
Rhea-AI Summary

IDEAYA Biosciences announced updates for its IDE397, a Phase 2 MAT2A inhibitor targeting MTAP-deletion solid tumors. A clinical data update is anticipated for H2 2024, covering over 15 evaluable MTAP lung and bladder cancer patients, including efficacy and molecular response analyses. The company is expanding IDE397 Phase 2 monotherapy to include bladder cancer, in addition to squamous lung cancer. Over 35 clinical trial sites have been activated globally for rapid enrollment. IDE397 is also involved in a Phase 1/2 trial with Amgen’s AMG 193 and preclinical combinations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags
-
Rhea-AI Summary

IDEAYA Biosciences announced promising Phase 2 results for darovasertib in treating neoadjuvant uveal melanoma (UM). The study, presented at the ASCO 2024 Annual Meeting, showed a 75% eye preservation rate and a median 47% tumor shrinkage in enucleation patients. Company-sponsored trials enrolled over 40 patients, with an observed median tumor shrinkage of 72% after 4 months and high eye preservation rates. IDEAYA plans a Type C FDA meeting in H2 2024 to discuss a registrational trial. Darovasertib demonstrated a manageable safety profile, with mostly low-grade adverse events. The global annual incidence of UM is estimated at 8,000-10,000 patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.4%
Tags
Rhea-AI Summary

On May 31, 2024, IDEAYA Biosciences, a precision medicine oncology company, announced the granting of non-qualified stock options to purchase 49,000 shares of its common stock to two new employees. The grants were made under the 2023 Employment Inducement Incentive Award Plan as per Nasdaq Listing Rule 5635(c)(4). The stock options, priced at $35.79 per share, match the closing price on the grant date. They have a 10-year term and vest over four years, with 25% vesting after one year and the remainder vesting monthly over the next three years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
none

FAQ

What is IDEAYA Biosciences, Inc.?

IDEAYA Biosciences, Inc. is a biotechnology company focused on the discovery and development of precision medicine therapies for oncology.

What is the primary focus of IDEAYA's research?

IDEAYA focuses on synthetic lethality and immuno-oncology, targeting DNA damage repair and the tumor microenvironment for genetically defined patient populations.

What is IDEAYA's product pipeline?

IDEAYA's pipeline includes IDE196 for cancers with GNAQ or GNA11 mutations, IDE397 for MTAP-deleted tumors, and IDE161 targeting tumors with homologous recombination deficiency (HRD).

Who are IDEAYA's key investors?

Key investors include 5AM Ventures, Canaan Partners, Celgene, WuXi Healthcare Ventures, Novartis Institute of Biomedical Research, and Alexandria Real Estate.

Where is IDEAYA Biosciences located?

IDEAYA has offices in South San Francisco and La Jolla, California.

What recent collaborations has IDEAYA announced?

IDEAYA has announced collaborations with Pfizer, Amgen, Gilead Sciences, GSK, and Merck to strengthen its research and clinical capabilities.

What significant achievements has IDEAYA made recently?

Significant achievements include promising Phase 2 trial results for IDE196 in uveal melanoma and the advancement of IDE397 and IDE161 in clinical trials.

What is IDEAYA's financial outlook?

As of Q1 2024, IDEAYA had cash and marketable securities totaling $941.4 million, projected to fund operations through 2028.

Who comprises IDEAYA's scientific advisory board?

IDEAYA's scientific advisory board includes a Nobel laureate and members of the National Academy of Sciences, underscoring their commitment to top-tier research.

How can I stay updated on IDEAYA Biosciences?

You can stay updated on IDEAYA Biosciences by visiting their Investor Relations page at https://ir.ideayabio.com/.

IDEAYA Biosciences, Inc.

Nasdaq:IDYA

IDYA Rankings

IDYA Stock Data

3.42B
84.04M
1.11%
108.54%
14.59%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
SOUTH SAN FRANCISCO